Regeneron (REGN) is rated a Buy ahead of its Q2 2026 earnings report expected around July 30, with analysts forecasting revenues of about $3.82 billion and EPS of $8.79. The company’s growth is driven by Dupixent's strong sales, the transition of Eylea to Eylea HD, and the emerging success of Libtayo. Despite some pipeline setbacks, promising new drugs like cemdisiran and olatorepatide support future growth. Regeneron also plans a $3 billion share buyback and has initiated dividends, targeting revenues over $14 billion in 2026 and aiming for $30 billion by 2030, implying over 40% upside potential for investors.
Regeneron Pharmaceuticals continues to be a Buy due to strong revenue growth driven by Dupixent's expanding uses and Libtayo's progress in oncology. Although shares have fallen from their peak around $1200 to about $660, the company’s solid pipeline,...
Telix Pharmaceuticals reported Q2 2026 revenue of $247 million, up 7% from the previous quarter and 21% year-over-year, driven by strong growth in its Precision Medicine segment. The company is progressing key clinical trials, including a Phase 3 stu...
